A US company plans to sell an unapproved gene therapy at overseas clinics that boosts production of klotho, a protein linked to aging and longevity. The approach circumvents FDA oversight by operating outside the United States.

Klotho functions as a tumor suppressor and regulates phosphate and calcium metabolism, processes that decline with age. Laboratory studies show that increasing klotho levels extends lifespan in mice and improves healthspan, the period of healthy aging. Human observational data suggests people with naturally higher klotho levels experience better kidney function and cardiovascular health as they age.

The therapy targets a genuine biological pathway. Researchers have documented that klotho expression drops in humans after age 40, correlating with age-related disease risk. Studies by teams at institutions including the Max Planck Institute demonstrate klotho's role in cellular senescence and inflammation. However, the jump from mouse models to human application remains substantial.

The company's plan reflects growing commercial pressure in longevity science. Direct-to-consumer anti-aging clinics increasingly offer experimental treatments without rigorous clinical trial data. This approach raises safety questions. Gene therapies carry risks including immune responses, off-target effects, and insertional mutagenesis depending on delivery method. The company has not published peer-reviewed efficacy or safety data for human use.

Regulatory agencies require extensive Phase 1, 2, and 3 trials documenting safety and efficacy before approval. These trials typically involve hundreds to thousands of participants tracked over years. The FDA's approval process, while sometimes slow, establishes baselines for both therapeutic benefit and adverse events. Overseas clinics operating without such oversight cannot track long-term outcomes systematically or report serious complications to regulators.

The availability of unapproved gene therapy overseas highlights a gap between scientific promise and clinical readiness. Klotho therapy may